» Go to news main
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Dr. Steven Burrell has published a new article in Le Patient Magazine!
Lutathera® lutetium (177lu) oxodotreotide for neuroendocrine tumours: a game changer concept in cancer treatment
Steven Burrell, MD, FRCPC Head of Nuclear Medicine QEII Health Sciences Centre
"When cancer has spread within the body the 2 main pillars of treatment are drugs such as chemotherapy which are administered internally and distribute throughout the body, and radiation which delivers tumour-destroying radiation from outside the body. However there is another approach..." Read more.
Recent News
- QEII welcomes the first GE StarGuide SPECT‑CT scanner in Canada.
- The first 68Ga‑PSMA PET scans in Atlantic Canada mark a new era in prostate cancer assessment
- Dr. David Volders awarded the Dr. Charles Lo Prize in Radiology Research
- Radiology Research Day 2024
- Program Administrator Award of Excellence
- Clinical practice guideline for management of osteoporosis and fracture prevention in Canada: 2023 update
- Dr. Siân Iles interviewed on CBC's Information Morning
- Dr. Steven Beyea and Dr. Adela Cora featured in the latest Beyond Research podcast from ResearchNS
Comments
comments powered by Disqus